Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

SGI-DNA touts its automated gene printer for coronavirus vaccine development

By Sean Whooley | March 24, 2020

Synthetic biology company SGI-DNA is touting its efforts to accelerate research in the creation of vaccines for SARS-CoV-2, the virus causing the COVID-19 pandemic.

The San Diego-based company said in a news release last month that it built the genes thought to be critical to developing successful vaccines against the virus and made those tools available as genomic assemblies and DNA libraries.

Using the company’s BioXp 3200 automated gene printing system that was used to create vaccines and therapeutics against the H7N9 bird flu in 2013, SGI-DNA hopes that it can provide its partners with a vehicle to develop vaccines for the coronavirus that has caused widespread crisis across the globe.

SGI-DNA is donating $50,000 toward the purchase of a BioXp 3200 system for researchers focused on the coronavirus outbreak, as well as other pandemics. The company’s goal is for the speed of its science to outpace the spread of the virus, according to SGI-DNA chief technology officer Dan Gibson.

“There is zero time to waste, which is why we’ve built resources for our partners and are co-funding purchases of the BioXp 3200 for anyone working on a vaccine or therapeutic treatment,” SGI-DNA CEO Todd Nelson said in the news release. “Researchers need synthetic DNA and RNA, which the BioXp 3200 can provide in as little as eight hours. We simply don’t have ‘six to eight weeks, or longer’ to wait.”


Filed Under: Genomics/Proteomics, Infectious Disease
Tagged With: coronavirus, covid-19, SGI-DNA
 

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Related Articles Read More >

Scanning electron micrograph of a cluster of Acinetobacter baumannii bacteria.
New antibiotics need AI that gets resistance right
New cell imaging method reveals hidden enzyme activity 
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE